Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Additional treated
View:
Post by Yajne on Mar 25, 2021 10:33am

Additional treated

Looks like two additional treated since the Q1 newsletter released, when they still needed to treat 11 to reach 25. One treated between Feb,1 and Feb 24 NR and one more during March so now "9" needed to achieve the magic "25 treated". Would be interesting to know where the last two were treated, I suspect it's in US where sites chosen are not competing with covid for beds. Hope that with six US sites now on board, they can complete at least "9" more fairly soon, which might be why Shirazi continues to use "early in 2021" language?
Comment by Rumpl3StiltSkin on Mar 25, 2021 11:42am
I'm guessing we get 100 easily treated in this study before it ends 'early' due to the 15 month CR of the first 25 happening by end of July 2022. We might see BDA prior to then, and Accelerated Approval ~ 90 days after that date. IMO What will the overall picture look like with that many optimally treated? What will the CR %s be? Share Price? :-)
Comment by tamarindo1 on Mar 25, 2021 12:11pm
The number of sites onboard and so far, the number of patients treated, apparently is not news that is impressing folks.  The RESULTS of those treated is the kind of news that will make this companies shares explode. 
Comment by rodrabal on Mar 25, 2021 12:25pm
Boy they are horrible promoters of there stock. Two additional people treated and only mention it as-  oooo by the way we have a couple more people in treatment. They should be emphasizing this information and tell us where they are being treated.What about patients 13-14. Where is that news. 180 days is up by now . Why are they keeping everthing so secret. This is really frustrating. 
Comment by Yajne on Mar 25, 2021 1:56pm
They seem to be following a "sublime" strategy...thinly veiled message buried in the NR and let all of us figure it out. Shawn did use the word 'excited' so I do sense at a pulse.
Comment by tamarindo1 on Mar 25, 2021 4:29pm
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250